Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profile of bladder cancer cell lines treated with Mitomycin C

ABSTRACT: Gene expression profile of bladder cancer cell lines treated with Mitomycin C

PROVIDER: PRJNA636096 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11881364_1.fastq.gz	Fastqsanger.gz
	SRR11881364_2.fastq.gz	Fastqsanger.gz
	SRR11881365_1.fastq.gz	Fastqsanger.gz
	SRR11881365_2.fastq.gz	Fastqsanger.gz
	SRR11881366_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 48

Similar Datasets

Gene expression profile of bladder cancer cell lines treated with Mitomycin C

Project description:Mitomycin C (MMC) is the gold standard treatment for non-muscle invasive bladder cancer (NMIBC). We aimed to evaluate in bladder cancer cell lines (T24, 5637, TCC-SUP and CLS-439) the transcriptomic response to MMC treatment. We used Gene Set Enrichment Analysis (GSEA) to identify biological processes and pathways modulated by MMC treatment.

2021-01-02 | GSE151505 | GEO

Expression data from mice bladder with MB49-induced cancer treated with alpha1-oleate alone or in combination Epirubicin or Mitomycin C, long-term effects

Project description:Bladder cancer is common and one of the most costly cancer forms, due to a lack of curative therapies. Recently, clinical safety and efficacy of the alpha1-oleate complex was demonstrated in a placebo-controlled study of non-muscle invasive bladder cancer. This study investigated if long-term therapeutic efficacy is improved by repeated treatment cycles and by combining alpha1-oleate with low-dose chemotherapy. Rapidly growing bladder tumors were treated by intravesical instillation of alpha1-oleate, Epirubicin or Mitomycin C alone or in combination. One treatment cycle arrested tumor growth, with a protective effect lasting at least four weeks in mice receiving 8.5 mM of alpha1-oleate alone or 1.7 mM of alpha-oleate combined with Epirubicin or Mitomycin C. Repeated treatment cycles extended protection, defined by a lack of bladder pathology and a virtual absence of bladder cancer-specific gene expression. Synergy with Epirubicin was detected at the lower alpha1-oleate concentration and alpha1-oleate was shown to enhance the uptake and nuclear translocation of Epirubicin, by tumor cells. Effects at the chromatin level affecting cell proliferation were further suggested by reduced BrdU incorporation. In addition, alpha1-oleate triggered DNA fragmentation, defined by the TUNEL assay. The results suggest that bladder cancer development may be prevented long-term in the murine model, by alpha1-oleate alone or in combination with low-dose Epirubicin. In addition, the combination of alpha1-oleate and Epirubicin reduced the size of established tumors. Exploring these potent preventive and therapeutic effects will be of immediate interest in patients with bladder cancer.

2023-02-25 | GSE209881 | GEO

Expression data from mice bladder with MB49-induced cancer treated with alpha1-oleate alone or in combination Epirubicin or Mitomycin C, short-term effects

2023-02-25 | GSE209882 | GEO

Oncopig and Human Bladder Cancer Cell Lines: Control vs Gemcitabine Treated

Project description:Transcriptional profiling of Oncopig and human bladder cancer cell lines comparing control untreated cells to cell treated with gemcitabine for 48 hours. Goal was to compare similar transcriptional alterations in response to gemcitabine treatment across both species

2024-02-16 | GSE255187 | GEO

Transcription profiling of mouse lymphoma L5178Y cells treated with Mitomycin C - ILSI-HESI Genotoxicity Study - Mitomycin

Project description:Mouse lymphoma L5178Y cells are treated with Mitomycin C [CAS:50-07-7;CHEBI:27504] and harvested at 4 and 24 hours for analysis.

2004-05-13 | E-TOXM-8 | biostudies-arrayexpress

Expression data of wild-type Salmonella enterica serovar Typhimurium strain 14028s treated with or without mitomycin C (3 μM)

Project description:We showed that treatment with mitomycin C results in activation of an endonuclease that cleaves tRNAs in the anticodon loop. In an attempt to identify this nuclease, we performed RNA-seq on wild-type cells treated with and without mitomycin C. Differential gene expression was performed to identify genes expressed upon mitomycin C treatment.

2020-12-22 | GSE153782 | GEO

Oncopig and Human Bladder Cancer Cell Lines: Control vs Gemcitabine Treated

Project description:Oncopig and Human Bladder Cancer Cell Lines: Control vs Gemcitabine Treated

| PRJNA1073916 | ENA

Transcriptomic profile of TP53 wildtype or knockout cells after treated with mitomycin C or vehicle

Project description:Transcriptomic profile of TP53 wildtype or knockout cells after treated with mitomycin C or vehicle

| PRJNA547615 | ENA

Next Generation Sequencing of total RNA from 9 bladder cancer cell lines and 3 fractionated bladder cancer cell lines

Project description:We profile the cell line expression of 279 circRNAs, that are highly expressed across 457 bladder cancer patient samples. Additionally, we investigate their cellular location in fractionated cell lines

2017-11-01 | GSE100971 | GEO

Transcriptomic profile of TP53 wildtype or knockout cells after treated with mitomycin C or vehicle

Project description:The goal of this study is to dig out how mitomycin C triggers apoptosis in the sensitive cells

2022-06-06 | GSE132327 | GEO